ArticlePCN reports : psychiatry and clinical neurosciences2025
Treatment of idiopathic hypersomnia with modafinil in an individual at clinical high risk for psychosis: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modafinil-associated psychosis: a systematic review of case characteristics and management strategies.Therapeutic advances in psychopharmacology · 2026Review
- Treatment of idiopathic hypersomnia with modafinil in an individual at clinical high risk for psychosis: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have shown that sleep disturbances are frequent at different stages of psychosis, including clinical high risk for psychosis (CHR-P). However, the comorbidity of hypersomnia with CHR-P and its treatment have rarely been reported or discussed. Case Presentation: A 16-year-old female diagnosed with major depressive disorder and CHR-P experienced worsening excessive daytime sleepiness (EDS), including falling sleep in class. Polysomnography and multiple sleep latency tests confirmed the diagnosis of idiopathic hypersomnia (IH), and treatment with modafinil (100 mg/day) was initiated. EDS improved after increasing the modafinil dose to 200 mg/day. No side effects or exacerbations of psychotic symptoms were observed. EDS recurred after she entered university and was treated with 300 mg/day of modafinil without side effects or transition to psychosis. Conclusion: This case demonstrates modafinil's efficacy and safety in treating IH in individuals with CHR-P. However, whether modafinil use increases the risk of transition to psychosis remains unclear. Further research is required on modafinil as a treatment for hypersomnia in individuals with CHR-P.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.